HMGCR and Alzheimer disease: Expression of SREBF1 (SREBP1 protein, which is involved in fatty acid synthesis) and ACACB (acetyl-CoA carboxylase-β, which is thought to inhibit fatty acid oxidation) were increased, while expression of SREBF2 (SREBP2 protein, which is involved in cholesterol synthesis), ACLY (ATP citrate lyase), FASN (fatty acid synthase), HMGCS1 (HMG-CoA synthetase), and HMGCR (HMG-CoA reductase) were significantly decreased in AD patients.